Hypertrichosis in females applying minoxidil topical solution and in normal controls

  title={Hypertrichosis in females applying minoxidil topical solution and in normal controls},
  author={Rpr Dawber and Jan Rundegren},
  journal={Journal of the European Academy of Dermatology and Venereology},
  • R. Dawber, J. Rundegren
  • Published 1 May 2003
  • Medicine
  • Journal of the European Academy of Dermatology and Venereology
Background  Hypertrichosis has been reported more frequently in females than in males who use minoxidil topical solution (MTS) for the treatment of androgenetic alopecia (AGA). This article examines the occurrence of MTS‐induced hypertrichosis in females. 
Infantile generalized hypertrichosis caused by topical minoxidil*
The first reported case in the Brazilian literature of generalized hypertrichosis affecting a 5-year-old child, following use of minoxidil 5%, 20 drops a day, for hair loss is presented.
Severe hypertrichosis in infants due to transdermic exposure to 5% and 7% topical minoxidil
Given the widespread use of topical minoxidil, it is likely that this etiology of childhood hypertrichosis is underdiagnosed and that it sometimes leads to minimal forms that go unnoticed.
Piggyback‐Acquired Hypertrichosis
A 9‐month‐old girl exposed to 5% topical minoxidil for 2 months developed generalized hypertrichosis of the exposed and unexposed areas of her body. The infant's grandfather had been using minoxidil
Androgenetic Alopecia: An Update of Treatment Options
The current treatment alternatives for androgenetic alopecia including their efficacy, safety profile, and quality of evidence are discussed.
Minoxidil and its use in hair disorders: a review
This article aims to review and update current information on the pharmacology, mechanism of action, clinical efficacy, and adverse events of topical minoxidil.
Reduction of telogen rate and increase of hair density in androgenetic alopecia by a cosmetic product: Results of a randomized, prospective, vehicle‐controlled double‐blind study in men
A large number of people in the world are affected by androgenetic alopecia, and the number of cases is expected to increase in the coming years.
An Open, Randomized, Comparative Study of Oral Finasteride and 5% Topical Minoxidil in Male Androgenetic Alopecia
Both drugs were effective and safe in the treatment of mild to severe AGA, although oral finasteride treatment was more effective (p < 0.05); side effects were all mild, and there was no need to stop the treatment.
Long-pulsed Nd:YAG laser in the treatment of facial hypertrichosis during topical minoxidil therapy
A case of fronto-temporal hypertrichosis occurring in an 8-year-old girl treated for patchy alopecia areata of the frontal area of the scalp with 2% minoxidil solution is reported.
Androgenetic Alopecia in Gender Minority Patients.


Diffuse hypertrichosis during treatment with 5% topical minoxidil
Five women affected by androgenetic alopecia developed severe hypertrichosis of the face and limbs after 2‐3 months of treatment with 5% topical minoxidil, and in all patients the hyper trichosis disappeared from theFace and arms after 1‐3 weeks, and from legs after 4‐5 months.
Minoxidil in the Treatment of Refractory Hypertension
Minoxidil, a powerful vasodilator, was used to treat 22 patients, most of whom were refractory to conventional antihypertensive medication, and there was a swift and definite drop of blood pressure in all cases.
Lack of efficacy of polysorbate 60 in the treatment of male pattern baldness.
Subject-reported new hair growth did not correlate with measurements, indicating that the placebo effect may be a major factor in reports of baldness "cures".
[Treatment for hair loss].
  • S. Wasielewski
  • Biology, Medicine
    Medizinische Monatsschrift fur Pharmazeuten
  • 2000
It is now known that the male hormone dihydrotestosterone (DHT) which is converted from testosterone by the enzyme 5 alpha reductase causes hair follicle to become progressively smaller and the hairs to become finer.
Minoxidil for severe hypertension after failure of other hypotensive drugs.
Patients with severe hypertension who were resistant to treatment with more conventional hypotensive drugs or could not tolerate the side effects were treated with minoxidil, a potent peripheral vasodilator, and this drug appears to be most effective in such patients.
Long term minoxidil therapy and renal function, cardiac function, hypertrichosis and blood pressure.
It is concluded that minoxidil is an effective agent in the long‐term treatment of severe, resistant hypertension not responding to more conventional therapy.
Once-a-day triple therapy with low-dose minoxidil for moderate hypertension.
It is concluded that, when added to a diuretic and a beta-blocker in a once-a-day regimen, minoxidil in a daily dose of less than or equal to 10 mg is effective and well tolerated in mild to moderate hypertension, especially in patients who are free of atherosclerotic complications.
The Effect of Once‐Daily Minoxidil on Blood Pressure and Plasma Lipids
Once‐daily minoxidil administration was added to the treatment regimen of 11 patients with hypertension that was inadequately controlled by nadolol 160 mg and chlorthalidone 50 mg given once daily, and changes in ratios of HDL cholesterol to either LDL or total cholesterol were seen.
Guide to clinical trials
A nonmathematical approach to statistics and data processing fundamental principles, considerations and techniques of the interpretation of clincal data interpreting of data from specific trials, modalities and populations issues and problems of clinical data interpretation are considered.